Merck, Inc.
🇵🇭Philippines
Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)
Phase 3
Completed
- Conditions
- Ankylosing SpondylitisAxial Spondyloarthritis
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 158
- Registration Number
- NCT00844805
Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00845000
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
Phase 2
Completed
- Conditions
- Depressive DisordersDepressionPsychotic Disorders
- Interventions
- Drug: PlaceboDrug: SCH 900636
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT00844922
A Study of ProQuad™ in Healthy Children in Korea (V221-023)
Phase 3
Terminated
- Conditions
- VaricellaRubellaMeaslesMumps
- Interventions
- Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)Biological: M-M-R™ II and Varivax™
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00839917
A Study of Single Dose Pain Therapy in Patients With Painful Diabetic Neuropathy (0000-115)
Phase 2
Withdrawn
- Conditions
- Painful Diabetic Neuropathy
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00837941
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT00837577
Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038)
Phase 2
Terminated
- Conditions
- Advanced Cancers
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2019-02-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT00836927
A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)
Phase 1
Terminated
- Conditions
- Rotavirus
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00836498
A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)
Phase 3
Completed
- Conditions
- Hepatitis A Virus Infection
- Interventions
- Biological: Hepatitis A Vaccine, Purified Inactivated (VAQTA™)
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 80
- Registration Number
- NCT00835380
Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
Phase 3
Completed
- Conditions
- HPV Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3006
- Registration Number
- NCT00834106
© Copyright 2025. All Rights Reserved by MedPath